Trials / Unknown
UnknownNCT06138483
A New Mutational and Epigenetic Signature to Predict Early OPSCC Relapse
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 267 (estimated)
- Sponsor
- Centro di Riferimento Oncologico - Aviano · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Inclusion of new biomarkers to improve the personalized treatment approach for HPV-positive and -negative oropharyngeal squamous cell carcinoma (OPSCC) patients is urgently needed. Emerging evidences suggest that mutations in epigenetic regulators, as well as epigenetic changes, deeply influence the biology of OPSCC, thus representing attractive targets for the definition of novel molecular markers for this malignancy. Based on these considerations, our project aims to retrospectively identify a new mutational and epigenetic signature to identify OPSCC patients at high risk of early relapse, and to set up a new multicenter prospective study in order to validate it
Conditions
Timeline
- Start date
- 2019-04-19
- Primary completion
- 2024-06-30
- Completion
- 2025-06-30
- First posted
- 2023-11-18
- Last updated
- 2023-11-18
Locations
5 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT06138483. Inclusion in this directory is not an endorsement.